- Home
- OWL vs IONS Comparison
OWL vs IONS Comparison
Compare OWL & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OWL
- IONS
- Stock Information
- Founded
- OWL 2020
- IONS 1989
- Country
- OWL United States
- IONS United States
- Employees
- OWL N/A
- IONS N/A
- Industry
- OWL Investment Managers
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- OWL Finance
- IONS Health Care
- Exchange
- OWL Nasdaq
- IONS Nasdaq
- Market Cap
- OWL 10.6B
- IONS 12.3B
- IPO Year
- OWL N/A
- IONS 1991
- Fundamental
- Price
- OWL $14.41
- IONS $80.64
- Analyst Decision
- OWL Buy
- IONS Strong Buy
- Analyst Count
- OWL 15
- IONS 21
- Target Price
- OWL $22.50
- IONS $80.71
- AVG Volume (30 Days)
- OWL 17.3M
- IONS 3.2M
- Earning Date
- OWL 10-30-2025
- IONS 10-29-2025
- Dividend Yield
- OWL 6.23%
- IONS N/A
- EPS Growth
- OWL 47.85
- IONS N/A
- EPS
- OWL 0.08
- IONS N/A
- Revenue
- OWL $2,745,943,000.00
- IONS $966,957,000.00
- Revenue This Year
- OWL $17.06
- IONS $27.96
- Revenue Next Year
- OWL $21.21
- IONS $2.33
- P/E Ratio
- OWL $186.36
- IONS N/A
- Revenue Growth
- OWL 27.24
- IONS 20.41
- 52 Week Low
- OWL $13.25
- IONS $23.95
- 52 Week High
- OWL $26.73
- IONS $81.17
- Technical
- Relative Strength Index (RSI)
- OWL 40.61
- IONS 68.95
- Support Level
- OWL $13.49
- IONS $71.83
- Resistance Level
- OWL $14.39
- IONS $74.50
- Average True Range (ATR)
- OWL 0.67
- IONS 3.41
- MACD
- OWL -0.00
- IONS 0.46
- Stochastic Oscillator
- OWL 43.96
- IONS 99.00
About OWL Blue Owl Capital Inc.
Blue Owl Capital Inc is an alternative asset management firm. The company deploys private capital across Credit, GP Strategic Capital, and Real Estate platforms on behalf of institutional and private wealth clients. The company conducts its operations through Blue Owl Capital Holdings LP (Blue Owl Holdings) and Blue Owl Capital Carry LP (Blue Owl Carry). Its investor base includes a diversified mix of institutional investors, including public and private pension funds, endowments, foundations, family offices, private banks, high-net-worth individuals, asset managers, and insurance companies. The company generates substantially all of its revenues in the United States.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.